Japan Intranasal Drug and Vaccine Delivery Market Size, Share, and COVID-19 Impact Analysis, By Product (Powder Delivery Device, Liquid Delivery Device, Pressurized Metered Dose Inhaler, and Others), By Dosage (Unit-Dose and Multi-Dose), By Application (Respiratory Disorders, Neurological Disorders, Vaccination, Pain Management, and Others), and Japan Intranasal Drug and Vaccine Delivery Market Insights, Industry Trend, Forecasts to 2035

Japan Intranasal Drug and Vaccine Delivery Market Insights Forecasts to 2035

• The Japan Intranasal Drug and Vaccine Delivery Market Size Was Estimated at USD 3094.8 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 7.16% from 2025 to 2035
• The Japan Intranasal Drug and Vaccine Delivery Market Size is Expected to Reach USD 6623.7 Million by 2035

According to a research report published by Spherical Insights & Consulting, The Japan Intranasal Drug And Vaccine Delivery Market Size is anticipated to reach USD 6623.7 Million by 2035, growing at a CAGR of 7.16% from 2025 to 2035. The Japan intranasal drug and vaccine delivery market is growing with the increasing R&D efforts by key players focused on launching innovative and effective nasal delivery products.

Market Overview

The Japan intranasal drug and vaccine delivery market is defined as non-invasive delivery systems that administer drugs and vaccines via the nasal mucosa. It is used for rapid drug absorption, prevention of first-pass metabolism, and effective treatment of respiratory, neurological, and infectious diseases. Intranasal delivery systems increase compliance by patients, particularly in children and geriatric populations, due to they are non-invasive. Prominent opportunities exist for expanding applications to drugs such as pain management and neurological therapies. Market growth is driven by the rising prevalence of respiratory and neurological disorders, patient preference for needle-free administration, and technological advancements in nasal delivery. The Japan regulatory supportive environment, led by the Pharmaceuticals and Medical Devices Agency (PMDA), facilitates approval of innovative drug delivery treatments more readily. The Sakigake Designation System also accelerates the development and approval process of transformative treatments, promoting subsequent innovation and growth in the intranasal drug and vaccine delivery market.

Report Coverage

This research report categorizes the market for the Japan intranasal drug and vaccine delivery market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan intranasal drug and vaccine delivery market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan intranasal drug and vaccine delivery market.

Driving Factors

The Japan intranasal vaccine and drug delivery market is fueled by the increasing incidence of respiratory and neurological diseases, which need effective treatment solutions. Patient need for needle-free and non-invasive delivery raises consumption, especially in children and older individuals. Advancements in nasal delivery systems improve drug efficacy and absorption. The COVID-19 pandemic fueled growth in intranasal vaccines, as a result of rapid deployment and ease of use. Government support policies and regulatory frameworks also propel innovation and market growth.

Restraining Factors

The Japanese intranasal drug and vaccine delivery market is restricted by regulatory challenges, costly development, and limited drug formulations suitable for nasal delivery. Additionally, issues of inflammation in the nose and variability in the absorption of drugs are restraints, slowing down growth in the market.

Market Segmentation

The Japan intranasal drug and vaccine delivery market share is classified into product, dosage, and application.

• The powder delivery device segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan intranasal drug and vaccine delivery market is segmented by product into powder delivery device, liquid delivery device, pressurized metered dose inhaler, and others. Among these, the powder delivery device segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is attributed to their ability to maintain vaccine stability without refrigeration. Their ease of administration, extended shelf life, and mobility make them especially convenient for mass immunization campaigns and remote health care to facilitate effective and comfortable delivery in diverse settings.

• The unit-dose segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan intranasal drug and vaccine delivery market is segmented by dosage into unit-dose and multi-dose. Among these, the unit-dose segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is owed to that single-use devices provide precise, sterile drug delivery that is appropriate for acute conditions like opioid overdose reversal, pain control, and immunization. Their portability, ease of use, and satisfactory patient compliance render unit-dose formats drug manufacturers' and public health agencies' drugs of choice.

• The respiratory disorders segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan intranasal drug and vaccine delivery market is segmented by application into respiratory disorders, neurological disorders, vaccination, pain management, and others. Among these, the respiratory disorders segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to their rapid onset and localized action on the nasal mucosa, making them a favorite option for treating acute and chronic respiratory conditions, driving long-term health demand for nasal drug products. Intranasal sprays have become common in the management of nasal allergies, chronic sinusitis, and upper respiratory infections.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan intranasal drug and vaccine delivery market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Tasei Kako Co. Ltd.
• Hisamistu Pharmaceutical Co., Ltd.
• 3M Company
• Novartis AG
• Santen Pharmaceutical Co., Ltd.
• Becton Dickinson and Company
• Antares Pharma Inc.
• Teva Pharmaceutical Industries Ltd
• Johnson & Johnson
• Shionogi & Co., Ltd.
• Kyowa Kirin Co., Ltd.
• Mylan N.V
• Bayer AG
• Others

Recent Developments:

• In August 2023, Shionogi & Co., Ltd. announced that its intranasal vaccine R&D for influenza and SARS-CoV-2, using a cationic nanogel (cCHP) delivery system, was selected for Japan’s SCARDA initiative under AMED’s vaccine/new modality research project, supporting advanced vaccine development and innovation.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan intranasal drug and vaccine delivery market based on the below-mentioned segments:

Japan Intranasal Drug and Vaccine Delivery Market, By Product

• Powder Delivery Device
• Liquid Delivery Device
• Pressurized Metered Dose Inhaler
• Others

Japan Intranasal Drug and Vaccine Delivery Market, By Dosage

• Unit-Dose
• Multi-Dose

Japan Intranasal Drug and Vaccine Delivery Market, By Application

• Respiratory Disorders
• Neurological Disorders
• Vaccination
• Pain Management
• Others